Topical Udonitrectag Formulation for Diabetic Ulcer Healing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for skin and mucous membrane diseases, particularly diabetic foot ulcers, are inadequate, and there is a lack of effective pharmaceutical remedies for conditions like diabetic ulcers that often lead to limb amputations.

Innovation Solution

A topical formulation of Udonitrectag, a non-peptide neurotrophin mimetic compound, is developed for treating dermatological diseases, including diabetic ulcers, using a semi-solid form or solutions like gels, emulgels, and emulsions, incorporating chelating agents and absorption promoters to enhance efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments (antibiotics, antimicrobials, wound disinfectants, creams, alginates, hydrocolloids, hydrogels, foams, specialized dressings) are used for diabetic foot ulcers, then wound coverage and basic care are provided, but effective healing is not achieved and amputation rates remain high

Engineering Contradiction:

Improvehealing effectivenessVSAvoidamputation rate

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent uses Udonitrectag as an intermediary substance that mediates between the damaged tissue and the healing process. This non-peptide neurotrophin mimetic compound acts as a mediator to stimulate endogenous healing mechanisms, specifically targeting microcirculation improvement and wound healing pathways without requiring complex external interventions or multiple conventional treatments

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention changes the fundamental parameter of treatment approach by using a small molecule compound (Udonitrectag) instead of large protein-based neurotrophins or conventional wound care products. This parameter change enables better pharmacokinetic properties, improved stability, and enhanced effectiveness in promoting wound healing and preventing amputations

Inventive Principle:

Principle #35Parameter changes

2Reliability

If native neurotrophins are used for wound healing, then strong anti-apoptotic effects and promotion of epithelial and endothelial cell survival are achieved, but poor pharmacokinetic properties prevent their use as drugs

Engineering Contradiction:

Improveanti-apoptotic effectVSAvoidpharmacokinetic property

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent creates a simplified copy of native neurotrophins by designing Udonitrectag, a non-peptide small molecule that mimics the key functional properties of neurotrophins. This copy retains the ability to bind TrkA and TrkB receptors and exert anti-apoptotic effects while eliminating the poor pharmacokinetic properties of the original protein-based neurotrophins

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The invention substitutes the complex protein structure of native neurotrophins with a simpler small molecule structure. This replacement maintains the essential biological activity (receptor binding and anti-apoptotic effect) while dramatically improving pharmacokinetic properties including stability, absorption, distribution, and ease of administration

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Data Source

PatentUS20260041694A1Udonitrectag For Topical Use In The Treatment Of Dermatological Diseases

Publication Date: 2026.02.12 MIMETECH

AI summary

The object of the present invention is Udonitrectag (or Negermin or MTS. IUPAC name (1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid lysine salt) and pharmaceutical formulation thereof for topical use for use in the treatment of dermatological diseases. i.e. of the skin and mucous membranes.